A look at a new blood-based circular RNA diagnostic platform and the Nature Medicine study motivating its commercial launch.
Key Takeaways
- CircRNA signature achieved AUC 0.945 for biomarker-confirmed Alzheimer's disease detection
- CircRNAs predicted progression with hazard ratio 2.92 versus pTau217's 1.81
- 34-circRNA panel was validated across three cohorts totaling over 2,400 participants